Exagen Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Exagen Inc. is a commercial-stage life sciences company specializing in autoimmune disease diagnostics, headquartered in Vista, California, and founded in 2002. The company develops and markets a comprehensive portfolio of proprietary diagnostic tests primarily for rheumatologists and other physicians to aid in the diagnosis, prognosis, and management of autoimmune connective tissue diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and vasculitis. Its core product line is the AVISE® portfolio, featuring nine key tests such as AVISE® CTD, a blood test that integrates cell-bound complement activation products (CB-CAPs) with traditional biomarkers to improve diagnostic accuracy for connective tissue diseases; AVISE® SLE for lupus diagnosis; AVISE® MTX for methotrexate drug level monitoring; and AVISE® Vasculitis to distinguish forms of vasculitis. The company also offers biomarkers for seronegative rheumatoid arthritis, including anti-PAD4 and anti-RA33, which are unique in the commercial market. Exagen's products combine proprietary serology, cell-based assays, algorithmic interpretation, and biomarker innovation to support earlier and more precise autoimmune disease diagnosis and treatment optimization. Recent major developments include the commercial launch of new biomarkers for seronegative rheumatoid arthritis (anti-PAD4), contributing to expanded revenue. In 2024 and 2025, Exagen secured incremental price increases for its AVISE® CTD test, raising the average selling price to over $400 per test, facilitated by successful reimbursement negotiations. The company closed a $20.2 million public offering in early 2025 and arranged a $25 million credit facility with Perceptive Advisors to refinance existing debt and support growth beyond financial and operational challenges. Exagen also advanced research dissemination by presenting multiple abstracts at major rheumatology conferences, underscoring ongoing investment in diagnostic innovation and personalized medicine for autoimmune diseases. The company projects full-year 2025 revenue between $65 million and $70 million with anticipated positive adjusted EBITDA by Q4 2025 and a path to sustainable free cash flow in 2026. Geographic operations focus primarily on the U.S. market with strategic expansion targeting approximately 5,000 rheumatologists nationwide. Exagen operates a CLIA-certified laboratory, supporting advanced autoimmune diagnostic testing with stringent quality control processes. The company markets its tests directly through a dedicated sales force and collaborates with healthcare and biopharma partners. It holds patents for key technologies like CB-CAPs and T cell markers and is considered a pioneer in the clinical validation of novel biomarkers for autoimmune diseases. Exagen’s business model leverages scientific innovation, clinical evidence, and commercial execution to serve rheumatologists and patients globally, positioning the company as a significant participant in precision diagnostics for complex autoimmune disorders. Exagen Inc. is publicly traded on NASDAQ under the ticker XGN. It continues to expand its diagnostic product line and clinical validation efforts while focusing on revenue growth, reimbursement optimization, and operational efficiency to achieve profitability and long-term value creation for shareholders.
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Q1 Earnings Call Highlights
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
Exagen Inc. Reports First Quarter 2026 Results
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of “Moderate Buy” by Analysts
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
Exagen Inc. (NASDAQ:XGN) Receives Average Rating of “Moderate Buy” from Analysts
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Exagen Inc. Announces Select Preliminary 2025 Financial Results
Exagen Inc. (NASDAQ:XGN) Given Consensus Rating of “Moderate Buy” by Analysts
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates